Sign in
WithdrawnNo phase

TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care

Key facts

Who runs it
STAVROS G DRAKOS
Where
Falls Church and Lexington, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Started
31 Mar 2025
Ended
1 Sept 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • CardioMEMS
Record updated
16 December 2024
Why it stopped
Did not receive funding from sponsor

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Severe clinical HF resistant to intensive medical therapy and requiring LVAD implantation
  • Left ventricular ejection fraction <=25% and cardiomegaly at time of LVAD implantation
  • Non-ischemic etiology of HF
  • Undergone LVAD implantation within prior 4 weeks or planned for LVAD implant
  • History of HF < 5 years
  • Body Mass Index <=35 kg/m\^2
  • Pulmonary artery branch diameter between 7 - 15 mm
  • Female subjects of childbearing age with negative urine or serum pregnancy test and agreeing to use reliable mechanical or hormonal form of contraception during study

Who cannot take part

  • History of previous cerebrovascular accident resulting in significant fixed motor deficit, limiting ability to perform exercise testing
  • Require acute or chronic renal replacement therapy within 3 months prior to enrollment
  • Participation in any other clinical investigations involving another Mechanical Circulating Support device or HF-related drug
  • Implantation of cardiac re-synchronization therapy < 3 months before enrollment
  • Implanted mechanical aortic and/or mitral valve(s) and/or right heart valve(s)
  • Irreversible multi-organ failure
  • Diagnosis of psychiatric disease, irreversible cognitive dysfunction or poor psycho-social issues likely to impair compliance with study protocol
  • Any condition that could limit survival to less than 2 years
  • History of cardiac or other organ transplant
  • Contraindicated to anti-coagulation, antiplatelet therapy, or diagnosis of coagulation disorders
  • Active infection
  • History of recurrent (>1) pulmonary embolism or deep vein thrombosis
  • Unable to tolerate right heart catheterization
  • Congenital heart disease
  • Hypersensitivity or allergy to aspirin and/or clopidogrel
  • Evidence of active acute myocarditis confirmed by histology
  • Aortic valve closure
  • Hypertrophic obstructive cardiomyopathy or sarcoidosis
  • Left ventricular end-diastolic diameter below normal (restrictive cardiomyopathy)

Where in United States

  • Inova Heart and Vascular InstituteFalls Church, United States
  • University of KentuckyLexington, United States

About the trial

What the trial wants to find out

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system CardioMEMS plus HF medications reverse-remodeling management.

The 2 groups in the trial

  • ControlNo study treatment, for comparison

    After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.

  • InterventionTreatment being tested

    After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.

    Treatment: CardioMEMS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Randomized-controlled, Non-blinded, Multi-center, Pilot Trial to Compare Standard-of-care LVAD Unloading Plus Heart Failure Medications Reverse-modeling Management Versus Hemodynamics-guided LVAD Unloading with the Use of the Wireless Monitoring System CardioMEMS Plus Heart Failure Medications Reverse-remodeling Management
Record updated
16 December 2024